Addressing gaps in treatment of AMD

Video

Aleksandra Rachitskaya, MD, speaks on the current gaps in AMD treatment as well as ongoing retinal advancements to help address unmeet needs of patients.

Aleksandra Rachitskaya, MD, retinal specialist of the Cole Eye Institute, Cleveland Clinic,speaks on the current gaps in AMD treatment as well as ongoing retinal advancements in work to help address unmeet needs of patients.

See more AMD Awareness content here, here, and here.

Related Videos
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Dr Ali Erginay discusses his EURETINA presentation
Varun Chaudhary speaks with David Hutton about the 2023 EURETINA congress
Related Content
Marco A. Zarbin, MD, PhD, Professor of Ophthalmology, Rutgers New Jersey Medical School

AAO 2023: Marco A. Zarbin, MD, PhD, provides analysis of the YOSEMITE and RHINE clinical trials

November 24th 2023
Article

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials

Documents indicate a corporation filing for bankruptcy. Image credit: ©Minerva Studio – stock.adobe.com

Oxurion NV will file for bankruptcy following KALAHARI data release

November 20th 2023
Article

In the clinical trial, Oxurion’s novel PKal Inhibitor, THR-149, did not meet its primary endpoint

Intraoperative fluorescein angiography with fluorescein mode, patient with pars planitis with peripheral leakage.

The future is now: Innovations in vitreoretinal surgery 3D viewing systems and robotics

November 16th 2023
Article

Developing technology may offer marked improvements in surgical precision

A photo of downtown London. Image credit: ©zgphotography – stock.adobe.com

MHRA issues UK marketing approval for Biocon Biologics biosimilar aflibercept (YESAFILI®)

November 13th 2023
Article

The company received marketing authorisation approval in the EU earlier this year

EMA recommends approval of high-dose intravitreal aflibercept (Eylea®) 8mg for nAMD and macular oedema

EMA recommends approval of high-dose intravitreal aflibercept (Eylea®) 8mg for nAMD and macular oedema

November 13th 2023
Article

The endorsement follows FDA approval in the United States this summer

Successful treatment of bilateral diffuse uveal melanocytic proliferation with plasmapheresis

Successful treatment of bilateral diffuse uveal melanocytic proliferation with plasmapheresis

November 10th 2023
Article

In this case study, a patient with recently diagnosed cancer demonstrated significant improvement for ocular symptoms of BDUMP following plasmapheresis

© 2023 MJH Life Sciences

All rights reserved.